New Weight-Loss Drugs Transform Obesity Treatments Amid High Costs and Accessibility Challenges

Despite promising results and unexpected cardiac benefits, concerns about potential adverse side effects and high costs pose significant challenges.

New weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound are transforming the way we approach weight management and obesity treatments.
These drugs, typically taken as regular injections, not only promote weight loss but also offer unexpected cardiac benefits.
However, high costs and poor accessibility pose challenges, as most private insurance companies and federal health programs do not cover weight-loss drugs.
Research has shown that these drugs may also help curb addictions to substances such as alcohol, nicotine and opioids.
Despite the promising results, there are concerns about potential adverse side effects such as gastrointestinal problems and muscle-mass loss.